Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 360 rue des Entrepreneurs MONTMAGNY QC G5V 4T1 |
Tel: | N/A |
Website: | https://groupedevonian.com |
IR: | See website |
Key People | ||
N/A |
Business Overview |
Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. It is also involved in the development of value-added products for dermo-cosmetics and the distribution of pharmaceutical products through its subsidiary. The Company's flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company's flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company's cosmeceutical products include R-Spinasome and Purgenesis. |
Financial Overview |
For the six months ended 31 January 2024, Devonian Health Group Inc revenues increased from C$863K to C$3.5M. Net loss decreased 14% to C$1.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Amortization of discount on convertible decrease from C$17K (expense) to C$0K, Amortization of discount on Canada Emerg decrease from C$4K (expense) to C$0K. |
Employees: | 6 as of Jul 31, 2023 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $31.31M as of Jan 31, 2024 |
Annual revenue (TTM): | $5.03M as of Jan 31, 2024 |
EBITDA (TTM): | -$3.59M as of Jan 31, 2024 |
Net annual income (TTM): | -$4.28M as of Jan 31, 2024 |
Free cash flow (TTM): | -$3.01M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 148,222,531 as of Mar 19, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |